Results 261 to 270 of about 95,190 (307)

The impact of JAK2V617F variant allele frequency in MPN patients following PEGylated interferon alpha discontinuation

British Journal of Haematology, EarlyView.
Treatment with pegylated interferon α resulted in a molecular response in 91% of patients with an average decrease in JAK2V61F VAF of 48.5% from baseline. In patients that discontinued treatment, the JAK2V617F VAF at the time of treatment discontinuation was the best indicator of durable remission over the 6‐month follow‐up period.
Ryan Brown, Rebekah Bennett, Clare Crean, Andrew Hindley, Julie McGimpsey, Nicholas Cunningham, Aaron Niblock, Suzanne McPherson, Kathryn Boyd, Allister Foy, Ciaren Graham, Graeme Greenfield, Mary Frances McMullin, Mark A. Catherwood   +13 more
wiley   +1 more source

Diagnosis and treatment of chronic lymphocytic leukemia: 2025 recommendations of the Brazilian Group of Chronic Lymphocytic Leukemia of the Brazilian Association of Hematology and Hemotherapy (ABHH). [PDF]

Hematol Transfus Cell Ther
Chiattone CS, Marques FM, Buccheri V, Yamamoto M, Fortier SC, Ikoma-Colturato MRV, Hamerschlak N, Figueiredo VLP, da Silveira TMB, Costa A, Laks D, Schaffel R, Barreto WG, Scheliga A, Fernandes PA, Nabhan SK, Gaiolla RD, Gonçalves MV, de Farias DLC, Ribeiro G, de Lacerda MP, Arrais-Rodrigues C, Brazilian Group of Chronic Lymphocytic Leukemia.   +22 more
europepmc   +1 more source

EUROCOVER-CLL: Reimbursement and accessibility of new treatments in relapsed/refractory chronic lymphocytic leukemia. [PDF]

Front Pharmacol
Monica M, Becirovic S, Bianchi-Manaila I, Duborija-Kovacevic N, Draganic P, Garouliene K, Hammerman A, Ispan F, Ivanova B, Männik A, Meresz G, Nazaryan L, Oleshchuk O, Savova A, Skoupa J, Stefanovic N, Tesar T, Kawalec P.   +17 more
europepmc   +1 more source

Efficacy, Toxicity and Effect of Pretreatment Cardiologic Consultation on Outcomes of Ibrutinib Therapy for Chronic Lymphocytic Leukemia-A KroHem Study. [PDF]

Cancers (Basel)
Mandac Smoljanović I, Aurer I, Bulj N, Dreta B, Miljak A, Petričević F, Ivić M, Bašić-Kinda S, Zatezalo V, Madunić S, Čaržavec D, Sinčić-Petričević J, Grohovac D, Jakšić O, Krečak I, Morić-Perić M, Coha B, Berneš P, Živković N, Pejša V.   +19 more
europepmc   +1 more source

Chronic lymphocytic leukemia.

Experimental oncology, 2013
openaire   +2 more sources

Invasive Cutaneous Mucormycosis in a Patient With Chronic Lymphocytic Leukemia on Obinutuzumab, Idelalisib, and Bruton Tyrosine Kinase Degrader: A Case Report. [PDF]

Cureus
Morinishi CD, Brown CE, Younes R.
europepmc   +1 more source

The Impact of Minimal Residual Disease Measurement in the Management of Chronic Lymphocytic Leukemia. [PDF]

Cancers (Basel)
Greenberg MR, Lucido T, Singh K, Rhodes JM.   +3 more
europepmc   +1 more source

IGHV1 usage is associated with lymphadenopathy and aggressive disease in the TCL1 mouse model for chronic lymphocytic leukemia

Drothler S, Scherhäufl C, Suete C, Parigger T, Gassner FJ, Pleyer L, Egle A, Greil R, Geisberger R, Zaborsky N.   +9 more
europepmc   +1 more source